Protocol Ledger

NCT03871829 · Phase II · TERMINATED

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Interventional Phase II clinical trial protocol NCT03871829 sponsored by Johnson & Johnson / Janssen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-05-31 Enrollment: 88 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03871829
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)88 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03871829
Protocol FieldVerified Registry Value
NCT IdentifierNCT03871829
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment88 participants (ACTUAL)
Registered Start Date2019-05-31
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03871829
Hospital Research SiteLocationSite Profile
Banner MD Anderson Cancer CenterGilbert, AZOpen Hospital Dossier ->
Mayo Clinic RochesterRochester, MNOpen Hospital Dossier ->
Washington University and Siteman Cancer CenterSaint Louis, MOOpen Hospital Dossier ->
Cleveland ClinicCleveland, OHOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI